RT info:eu-repo/semantics/article
T1 Cell culture-derived flu vaccine: Present and future
A1 Pérez Rubio, Alberto
A1 Eiros Bouza, José María
K1 Vacuna
K1 Influenza
K1 32 Ciencias Médicas
AB The benefit of influenza vaccines is difficult to estimate due to the complexity of accurately assessing the burden of influenza. To improve the efficacy of influenza vaccines, vaccine manufacturers have developed quadrivalent influenza vaccine (QIV) formulations for seasonal vaccination by including both influenza B lineages. Three parallel approaches for producing influenza vaccines are attracting the interest of many vaccine manufacturing companies. The first and oldest is the conventional egg-derived influenza vaccine, which is used by the current licensed influenza vaccines. The second approach is a cell culture-derived influenza vaccine, and the third and most recent is synthetic vaccines. Here, we analyze the difficulties with vaccines production in eggs and compare this to cell culture-derived influenza vaccines and discuss the future of cell culture-derived QIVs.Keywords: Influenza vaccine, cell culture-derived, quadrivalent.
PB Taylor & Francis
SN 2164-5515
YR 2018
FD 2018
LK http://uvadoc.uva.es/handle/10324/44628
UL http://uvadoc.uva.es/handle/10324/44628
LA eng
NO Human Vaccines & Immunotherapeutics, 2018, vol. 14, n. 8, p. 1874-1882
NO Producción Científica
DS UVaDOC
RD 12-sep-2024